Anzeige
Mehr »
Login
Freitag, 12.08.2022 Börsentäglich über 12.000 News von 669 internationalen Medien
Innocan Pharma: 15 Mal besser als der Status Quo!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 ISIN: US8006771062 Ticker-Symbol: GBY 
Tradegate
12.08.22
17:33 Uhr
6,081 Euro
+0,434
+7,69 %
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,0936,15019:22
6,0936,15119:22

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoXETR DELETION OF INSTRUMENTS FROM XETRA - 11.08.2022821The following instruments on XETRA do have their last trading day on 11.08.2022.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 11.08.2022.ISIN NameUS0028962076 Abercrombie & Fitch...
► Artikel lesen
DiSANGAMO THERAPEUTICS, INC - 8-K, Current Report9
04.08.SANGAMO THERAPEUTICS, INC - 10-Q, Quarterly Report19
SANGAMO THERAPEUTICS Aktie jetzt für 0€ handeln
21.07.Sangamo's TX200 gets orphan drug tag in EU for use in organ transplant11
21.07.Sangamo Therapeutics, Inc.: European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation363Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned...
► Artikel lesen
20.07.SGMO, IMGN and BPOP are among after hour movers14
13.06.Sangamo Therapeutics begun at neutral at Wedbush on 'frontrunner' Fabry candidate30
01.06.NRDS, PTGX and SGMO are among after hour movers11
01.06.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences372Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date:...
► Artikel lesen
25.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report11
06.05.Sangamo Therapeutics stock slips despite Q1 revenue beat35
05.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report17
05.05.Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M14
02.05.Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)382Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation...
► Artikel lesen
29.03.Sangamo begins dosing in trial of TX200 for preventing kidney transplant rejection31
23.03.ADPT, SGMO and RDBX among after hour movers21
25.02.Sangamo Therapeutics rises 5% after hours following Q4 earnings27
08.02.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease544Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited...
► Artikel lesen
06.01.Sangamo Says Sanofi To Transition Sickle Cell Disease Program Back To Sangamo668PARIS (dpa-AFX) - Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF, SNY) will be transitioning its rights and obligations related...
► Artikel lesen
12.12.21Sangamo Therapeutics, Inc.: Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy669Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,11